Novo Nordisk filed a lawsuit on Monday against Hims & Hers Health, alleging that the U.S. telehealth company infringed its patents by selling compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, used for diabetes and weight loss. Compounding is a legal process that allows U.S. drug manufacturers to produce and sell unapproved medications tailored to meet specific patient needs.
Novo Nordisk Sues Hims & Hers Over Ozempic Copycat Drug